October
01
 

Nitschke makes headlines again

Dr Philip Nitschke, founder of euthanasia group Exit International, made headlines yet again this week when he announced that he will import the suicide drug Nembutal to Australia. He has said that he intends to exploit a “loophole” in the Therapeutic Goods Administration’s regulations on medicine to import the drug for a woman in South Australia. However, as a anti-euthanasia campaigner Paul Russell suggests, it may be a lot of hot air – the “loophole” to which Nitschke refers may not actually exist.

Nitschke says the TGA has approved the importation – which it has not – and that he intends to import Nembutal under a provision in the TGA’s guidelines for unregistered medicines. These guidelines explicitly state that medicines in this category must be for treating life-threatening diseases with medicines which have not undergone formal clinical trials. While Nembutal was once used as a sedative, its primary function at present is to euthanase animals and humans. ~ Sydney Morning Herald, Sep 27; Careful!, Sep 27; London Telegraph, Sep 26




 

 Search BioEdge

 Subscribe to BioEdge newsletter
rss Subscribe to BioEdge RSS feed

 Best of the web

 Recent Posts
Jolie’s Choice
18 May 2013
DSM-5 to be launched next week
18 May 2013
Breakthrough in therapeutic cloning reignites debate
18 May 2013
Are bioethicists a “priestly caste”?
18 May 2013
Is surgical castration is an ethical option for sex offenders?
18 May 2013

 Tags
IVF, stem cells, bioethics, law, US, human drama, euthanasia, embryonic stem cells, commercialization, sperm donation, assisted suicide, India, abortion, Germany, Netherlands, organ trafficking, clinical trials, enhancement, Canada, China, informed consent, surrogacy, UK, Australia, Julian Savulescu, suicide, genetic testing, organ donation, neuroscience, Down syndrome,